Characterizing moderate penetrance susceptibility genes is an emerging frontier in colorectal cancer (CRC) research. GALNT12 is a strong candidate CRC-susceptibility gene given previous linkage and association studies, and inactivating somatic and germline alleles in CRC patients. Previously, we found rare segregating germline GALNT12 variants in a clinic-based cohort (N = 118) with predisposition for CRC. Here, we screened a new population-based cohort of incident CRC cases (N = 479) for rare (MAF ≤1%) deleterious germline GALNT12 variants. GALNT12 screening revealed eight rare variants. Two variants were previously described (p.Asp303Asn, p.Arg297Trp), and additionally, we found six other rare variants: five missense (p.His101Gln, p.Ile142Thr, p.Glu239Gln, p.Thr286Met, p.Val290Phe) and one putative splice-altering variant (c.732-8 G>T).
INTRODUCTION
Unraveling the genetic predisposition to colorectal cancer (CRC) is a subject of global significance (Rafiemanesh et al., 2016; Valle, 2014) .
Since the elucidation of mismatch repair (MMR) genes in hereditary CRC, the search for new and highly penetrant CRC-susceptibility genes has yielded diminishing returns. Indeed, recent studies now postulate that the existence of any major high penetrance susceptibility genes, of similar caliber as the MMR genes and APC, is unlikely (Chubb et al., 2016) . This emphasizes the increasing relevance of CRC-susceptibility models that recognize the impact of rare alleles with modest effect sizes; which are difficult to detect by classic approaches such as genome-wide association and family-based linkage studies, yet could explain a sizeable fraction of the missing heritability in CRC (Hahn et al., 2016; Manolio et al., 2009) . The genetic investigation of large and well-characterized patient cohorts is a useful way to identify moderate penetrance variants. Although high penetrance variants are often the most clinically actionable, CRC screening guidelines now recognize moderate penetrance alleles in APC, CHEK2, and MUTYH (Tung et al., 2016) . With the genetic architecture of CRC becoming increasingly apparent, and the role of moderate penetrance genes becoming a new focus, this study explores GALNT12 (MIM# 610290, RefSeq: NM_024642.4) as a moderate penetrance gene for CRC susceptibility.
The initiation of mucin-type O-linked glycosylation is governed by the GALNT family of enzymes (Brockhausen, Schachter, & Stanley, 2009) , and glycosylation plays a vital role in regulating key cellular functions including adhesion, migration, and immune surveillance (Ohtsubo & Marth, 2006) . PpGalNAc-T12 (encoded by GALNT12) is highly expressed in normal colon tissue and downregulated in colonic cancers (Guo et al., 2002; Guo, Chen, Wang, Zhang, & Narimatsu, 2004) . Aberrant glycosylation can impair the normal functioning of lipids and proteins by affecting cellular glycan structure (Pinho & Reis, 2015; Stowell, Ju, & Cummings, 2015) and is a hallmark of several different cancers; including CRC (Bergstrom & Xia, 2013; Brockhausen, 2006) . It is unsurprising, therefore, that genetic and epigenetic defects underlying the O-linked pathway are proposed to contribute to CRC pathogenesis (Brockhausen, 2006; Brockhausen et al., 2009; Tran & Ten Hagen, 2013) .
Genetic evidence demonstrates that GALNT12 is a candidate CRC-susceptibility gene; as we and others have identified a CRCsusceptibility locus spanning 9q22.32-31.1 (Gray-McGuire et al., 2010; Skoglund et al., 2006; Wiesner et al., 2003) and GALNT12 resides in the 6.5cM critical interval (markers D9S1851-D9S277) within this region (Kemp et al., 2006) . Bolstered by functional evidence showing that inactivating GALNT12 alleles are over-represented in CRC cell lines (Guda et al., 2009) , we previously characterized GALNT12 in a clinicbased discovery cohort (N = 118) with predilection for CRC, and identified rare and segregating GALNT12 alleles in high-risk CRC families (Clarke et al., 2012) .
Here, our aim was to expand the investigation of GALNT12 by screening for rare and deleterious alleles in a larger and wellcharacterized population-based cohort of incident CRC cases (N = 479) from the province of Newfoundland & Labrador (NL). This island of Atlantic Canada harbors unique founder populations of predominantly English and Irish descent, and is well-suited for genetic research; given geographic and historical isolation (Mannion, 1977) , and willingness to participate in research studies. With one of the highest reported incidence rates of familial CRC in the world , and the highest incidence rate of CRC reported in Canada (Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2015) , the NL population offers an invaluable opportunity to study the genetic etiology of CRC (Rahman et al., 2003; Zhai et al., 2016) .
This was most significantly demonstrated by "Family C," an NL kindred that helped elucidate the role of MSH2 in hereditary CRC (Leach et al., 1993) .
To further our investigation into the putative association of GALNT12 defects and CRC susceptibility, leveraging the unique attributes of the NL population, we examined the germline DNAs of 479 incident CRC cases from the Newfoundland Colorectal Cancer Registry (NFCCR) . Herein, we describe novel findings of rare and deleterious GALNT12 alleles in CRC patients, which cluster around the glycosyl-transferase domain, and functionally impair this enzyme.
METHODS

NFCCR and population-matched controls
During the prior NFCCR study, all pathologically confirmed incident CRC cases that occurred over a 5-year period (January 1, 1999 to December 31, 2003 , with diagnosis under the age of 75, were identified through provincial tumor registries . After providing written and informed consent, study participants completed family history and risk factor questionnaires and provided access to blood samples, tumor tissues, medical records and gave permission for kin contact. As well, a cohort of CRC-free population controls was ascertained through random digit dialing (Raptis et al., 2007; Wang et al., 2009) . After providing written and informed consent, population control participants provided family history, personal history and diet questionnaires, as well as blood samples for DNA extraction.
Patients of the NFCCR cohort have previously been screened for MMR gene variants and microsatellite instability (MSI) (Woods et al., 2010) . MMR gene variants were assessed for pathogenicity using the InSiGHT variant database (Thompson et al., 2014) . We assigned familial CRC risk criteria based on relationship to the proband of each family.
Risk criteria included in this study were the Amsterdam Criteria-1 (AC-1) (Vasen, Mecklin, Khan, & Lynch, 1991) , the Age and Cancer Modified Amsterdam Criteria (ACMAC) (Woods et al., 2005) , the Revised Bethesda Criteria (Umar et al., 2004) , and criteria for Familial Colorectal Cancer Type X (FCCTX) (Lindor, 2009 ).
During the current study, we chose germline DNAs of 479 NFCCR cases and 400 population-matched CRC-free controls, which then underwent GALNT12 screening. We were blind to both MMR variant and microsatellite status during the study. The Health Research Ethics Authority of Newfoundland & Labrador granted approval for this study (HREB # 2010.035).
Sanger DNA sequencing and variant interpretation
CRC cases and population controls were sequenced using Sanger sequencing. Primer design was followed as per previous studies (Guda et al., 2009 ) and PCR amplification was performed for all 10 exons and intronic boundaries of GALNT12 (conditions available upon request). The GALNT12 RefSeq (NM_024642.4) and the canonical transcript (ENST00000375011.3) were selected using Ensembl genome browser, with the GRCh38.p10 reference genome assembly (Zerbino et al., 2018) . Standard sequencing protocols for automated sequencing on an ABI 3130XL Genetic Analyzer (Applied Biosystems by Life Technologies, Carlsbad, CA, USA) were followed. Sequencing data was then analyzed and interpreted using Sequencing Analysis 5. Minor allele frequency (MAF) was assessed using publically available databases including: dbSNP (Sherry et al., 2001) , the NHLBI exome variant server (NHLBI GO Exome Sequencing Project, Seattle, WA; URL https://evs.gs.washington.edu/EVS), the ExAC browser and the GnomAD browser . We calculated the maximum credible allele frequency of a CRC variant, and variant penetrance, using GnomAD frequencies (Whiffin et al., 2017 ) (Supp. Methods). A GALNT12 variant MAF threshold of ≤1% in more than one population database was used to identify candidate variants.
For each variant, bioinformatics tools including SIFT (Sim et al., 2012) , Polyphen-2 (Adzhubei, Jordan, & Sunyaev, 2013) , CADD (Kircher et al., 2014) , and REVEL (Ioannidis et al., 2016) 
Generation of secreted pIHV constructs
A GALNT12 cDNA fragment excluding the N-terminal transmembrane domain, corresponding to amino acids 38-581, was amplified by RT-PCR from RNA of a normal control as described previously (Guda et al., 2009) 
Cell lines and DNA transfection
SW480 cells were obtained from American Type Culture Collection (ATCC) in 2012, tested for authenticity using short tandem repeat genotyping at least 3 months prior to experimental assessments, and screened periodically for mycoplasma contamination using the MycoAlert mycoplasma detection kit (Lonza, Basel, Switzerland).
Transfection was performed using Lipofectamine 2000 (Life Technologies) according to standard protocol. Briefly, 10 6 SW480 cells were plated per 100-mm dish 24 hr before transfection, and incubated in 5% CO 2 at 37 • C overnight. Four micrograms of plasmid DNA was used per 100-mm dish.
Recombinant protein purification
The cell monolayers were washed twice with ice-cold PBS and incubated with lysis buffer (50 mM Tris, pH 7.5/150 mM NaCl/1 m MCaCl 2 /1 mM MnCl 2 /EDTA-free protease inhibitor pellets/ 0.3% CHAPS) for 15 min on ice. After scraping, the lysates were clarified by centrifugation for 15 min at maximal speed. The recombinant protein was immunoprecipitated from the lysates using anti-V5 agarose beads (Sigma-Aldrich, St Louis, MO), and subsequently washed with wash buffer (50 mM Tris, pH 7.5/150 mM NaCl/1 mM CaCl 2 /1 mM MnCl 2 /EDTA-free protease inhibitor pellets). 
Western blot analysis
Enzymatic assay for GALNT12 variants
Negative control (empty vector), positive control (wild-type GALNT12), and missense mutant versions of GALNT12-bound beads were added to transferase-specific reaction mixtures in 1.5 ml is an optimal peptide substrate specifically determined for ppGalNAc T12 by the Gerken Lab (Gerken et al., 2011) and custom synthesized by RS Synthesis. A 10 mmol stock solution of OPT-T12 substrate was prepared by lyophilizing from water several times and adjusting to pH 7.4 with dilute NaOH/HCL. Reagent reaction mixtures were combined with 100 l transferase-bound beads to a final reaction volume of 250 l. The pH of the total reaction was adjusted to 6.8 and the mixture was agitated at 37 • C in a TAITEC shaking Microincubator M-36 to maintain the beads in suspension. Following an overnight incubation, reaction mixtures were quenched with an equal volume of 250 mM EDTA and frozen for later processing. UDP and nonhydrolyzed UDP-GalNAc were removed by passing the sample through a column of ∼3 ml of Dowex 1 × 8 anion exchange resin (Acros Organics, Thermo Fisher Scientific, Pittsburg, PA). Subsequently, eluents were lyophilized, reconstituted with water to a final volume of 1 ml and passed through G10 columns. [ 3 H]-GalNAc incorporation onto the OPT-T12 substrate was determined by scintillation counting on a Beckman LS5801 scintillation counter, whereas absorbance at 220 nm and 280 nm was measured using a spectrophotometer. Transferase activity at each time point was calculated as a ratio of the post-G10 counts to the absorbance at 220 nm. Mutant transferase-specific activities were then normalized to the WT transferase to yield an approximate relative specific activity of each mutant. The specific activities of the wild-type, and each of the GALNT12 mutants, were assayed and were expressed as the average activity derived from three independent biological replicates per experimental arm.
Statistical analyses
Transferase activities of wild-type and mutant GALNT12 proteins were compared using a Student's t-test, with a P value ≤ 0.05 considered statistically significant. A one-sided Fisher's exact test was used to compare the frequency of GALNT12 variants in CRC cases and population-matched controls, with a P value of ≤0.05 considered statistically significant.
RESULTS
Germline DNA sequencing of 479 NFCCR cases revealed 21 polymorphisms in GALNT12 (Supp. Table S1 ). Analysis of rare (MAF ≤1%) GALNT12 variants identified eight candidates for further study (Table 1) Table S2 ). The eight candidate GALNT12 variants were sequenced in a population-matched CRC-free control cohort (N = 400). Control sequencing revealed these eight variants were over-represented in CRC cases compared to populationmatched CRC-free controls (P = 0.03814), with the p.Asp303Asn and p.Arg297Trp variants each found in a single control, respectively (Table 1 and Supp. Figure S1 ). Using multiple in silico tools (SIFT, Polyphen, CADD, REVEL), consequences of GALNT12 variants were predicted (Table 1) . Missense variants scored deleterious according to CADD, SIFT, and Polyphen-2. CADD scores were highly deleterious, ranging from 24.8 (p.Asp303Asn) to 34.0 (p.Thr286Met).
GALNT12 variants clustered within or near the glycosyl-transferase domain encoded by GALNT12 (Figure 2 ). Transferase activity of missense variants was characterized using an in vitro-derived peptide substrate assay (Figure 3) . Three of the newly identified GALNT12 missense variants (p.His101Gln, p.Ile142Thr, p.Val290Phe) demonstrated a marked loss (>2-fold reduction) of enzymatic activity compared with the wild-type protein (P ≤ 0.05), whereas the p.Glu239Gln variant exhibited a ∼2-fold reduction in enzymatic activity (P = 0.077). Additionally, we tested the p.Tyr396Cys allele identified in our previous study (Clarke et al., 2012) , which demonstrated a significant loss in GALNT12 activity (P ≤ 0.05).
TA B L E 1 Rare GALNT12 variants identified in a population-based cohort of 479 incident CRC cases from Newfoundland (Clarke et al., 2012) and was included in this in vitro enzyme assay to test its enzymatic potential
In silico tools (Spliceman, Human Splicing Finder, Spliceview) were used to predict consequences of the putative splice-altering variant (c.732-8G>T), as RNA was not accessible for this family living in a rural and remote area (Supp. Methods). Predictions were discordant, as Spliceman predicted high probability of disrupted splicing (L1 81%), whereas Human Splicing Finder predicted alteration of an exonic splice silencing site or alternatively no effect, while Spliceview predicted no influence on splicing.
The eight rare GALNT12 variants were derived from probands of 10 unrelated families, with p.Asp303Asn represented in 3 unrelated families ( Figure 1 ). We proceeded with familial cosegregation analysis to assess penetrance. DNA was not available for segregation analysis in nine out of 10 families, and many relatives were deceased at the time of study. Segregation was tested in Family 1117 (Figure 1 ), as DNA was available for two distant CRC-affected relatives of the proband (first cousins once removed). Neither carried the p.Asp303Asn variant, and it is unclear whether the proband's risk for CRC derives from the paternal or maternal lineages. Our limited cosegregation analysis was therefore inconclusive, but not supportive of p.Asp303Asn segregation (Supp. Figure S2 ). Given the limited DNA available for segregation analysis, we estimated the penetrance Whiffin et al., 2017) under different assumptions for the NL population (Supp. Methods). We observed evidence of moderate penetrance for these GALNT12 variants (Supp . Table S3 ). Table 2 shows the clinical and molecular characteristics of CRC probands carrying the rare GALNT12 variants. The age of proband CRC diagnosis ranged from 43 to 72 years. Patients of the NFCCR cohort were screened for MMR defects or MSI during prior studies (Woods et al., 2010) , and during this study, we had no a priori knowledge of patient MMR status. We found that the majority of probands with rare GALNT12 variants (eight out of 10) were microsatellite stable (MSS) and MMR proficient. Probands from two families (Figure 1: 1575, 1595) harbored pathogenic (InSiGHT class 5) MMR gene variants with high tumor microsatellite instability (MSI-H) (Table 2) . Finally,
we assessed risk of genetic predisposition for CRC in all families using established risk criteria. Two families (Figure 1 : 1595, 1541) fulfilled the AC-1 (Vasen et al., 1991) . Of these two AC-1 families, the proband of Family 1595 was MSI-H and MLH1 deficient, whereas the proband of Family 1541 was MSS and MMR proficient; meeting criteria for FCCTX. A total of five families met the Revised Bethesda Criteria (Umar et al., 2004) . Two were the AC-1 families described above, and of the remaining three, one was MSI-H and MSH6 deficient, whereas two families were MSS and MMR intact.
DISCUSSION
Here, we screened a population-based cohort of 479 incident CRC cases, identifying eight rare GALNT12 variants (Table 1) . We observed a higher burden of these variants in CRC cases compared to populationmatched CRC-free controls (P ≤ 0.05). Multiple in silico tools (CADD, SIFT, and Polyphen-2) predicted these missense variants are deleterious (Table 1) , and variants clustered within or near the functionally relevant glycosyl-transferase domain (Figure 2 ). Transferase assays revealed GALNT12 mutants demonstrate a marked reduction of enzyme activity compared to wild-type (Figure 3 ).
To explore GALNT12 variation in this study, we chose a rare variant MAF threshold of ≤1%. This allowed us to assess rare variants under reduced penetrance, and consider the potential for NL founder effects.
Recently, Whiffin et al. (2017) proposed a strategy that leverages allele frequencies available in large population databases to assess maximum credible allele frequencies. Predicted maximum credible allele frequencies for CRC variants in NL are shown under different models of penetrance in Supp. Table S2 . For example, under 50% penetrance, we estimated a MAF of no greater than 0.00997%, or 37 GnomAD alleles (Supp. Methods). This analysis however, does not consider the potential for genetic drift in our founder population. During the analysis, we also noted a limitation, as the most common known pathogenic CRC variant in NL, a founder variant in MSH2 (p.Val265_Gln314del), greatly exceeds our calculated maximum credible allele frequencies, with a GnomAD MAF of 1.125% (330 alleles out of 29,332 total alleles; 18 homozygotes). This pathogenic variant is known to cause CRC in multiple families around the world, and explains up to 71% of CRC caused by MSH2 in NL (Woods et al., 2010) . This finding likely arises from a very high number of false positive calls, due to low sequence complexity in this region; highlighting a confounding variable in using these large databases, which rely on next-generation DNA sequencing technology. We advocate for a cautious approach to relying on expected frequencies as a sole indicator of pathogenicity. Ultimately, we observed that a majority of GALNT12 variants identified in this study were well below 0.02% global MAF.
Bioinformatic tools (SIFT, Polyphen-2) are well established for predicting consequences of genetic variation (Dong et al., 2015) . SIFT assumes variation within evolutionarily conserved regions is more likely to impact protein function (Sim et al., 2012) , whereas Polyphen-2 considers sequence-based, phylogenetic and structural features to predict consequences (Adzhubei et al., 2013) . We observed agreement between SIFT and Polyphen-2 in predicting deleterious consequences for GALNT12 missense variants (Table 1 ). The sole exception was p.Asp303Asn; which SIFT predicted "tolerated," whereas Polyphen-2 predicted "probably damaging." A limitation of these tools is that they cannot predict intronic variation. Newer ensemble prediction tools such as CADD and REVEL are gaining favor since they incorporate weighted estimates using multiple in silico tools, trained on machinelearning algorithms, to assist in variant interpretation (Ioannidis et al., 2016; Kircher et al., 2014) . CADD scores have demonstrated clinical utility for interpreting MMR variants in a manually curated dataset from InSiGHT (van der Velde et al., 2015) . We observed highly deleterious CADD scores (24.8-34.0) for all GALNT12 missense variants (Table 1) . REVEL scores predicted two GALNT12 variants (p.Ile142Thr, p.Glu239Gln) are deleterious (score > 0.5); thus CADD and REVEL were not concordant. Though both tools have merits, they are limited by circular errors that arise from benchmarking datasets (Grimm et al., 2015) . Overall, rare missense GALNT12 variants were predicted deleterious according to three programs-CADD, SIFT, and Polyphen-2.
Since these deleterious variants clustered around the glycosyltransferase domain (Figure 2 ), we postulated that assaying enzyme activity might further delineate any consequences of these variants.
Accordingly, we characterized mutant enzyme activities using an in vitro peptide derived assay (Figure 3 ). We observed that GALNT12 (Figure 3 ). This observation suggests our assay is likely to underestimate the reduction of enzyme activity seen in mutants. The consistent differences in GALNT12 expression could result from a compensatory mechanism arising from altered protein stability. Taken together, our enzymatic assays provided corroborating evidence for the deleterious effects of GALNT12 variants.
Due to our ascertainment method (incident cases), were not able to pursue familial cosegregation analysis for most GALNT12 variants in this study; given that additional DNAs were not available for nine out of 10 families. We tested segregation of p.Asp303Asn in Family 1117
( Figure 1) . The results did not support segregation, though pedigree structure and limited DNA sample numbers rendered the analysis inconclusive (Supp. Figure S2) . Recently, Whiffin et al. (2017) proposed a strategy to estimate variant penetrance using allele frequencies in large population databases . Using prevalence of CRC in NL and lifetime CRC risk in Canada (Supp. Methods), we estimated penetrance of GALNT12 variants (Supp. (Abdelfatah et al., 2013) . Thus, two pathogenic variants for a monogenic disease can, and do co-occur within NL families. Further study encompassing a broader array of populations will be useful to delineate the role of these GALNT12 variants.
In total, three non-Lynch Syndrome families met the Revised Bethesda Criteria, with one family meeting criteria for FCCTX (Table 2) . Recently, germline DNA sequencing of GALNT12 in a Spanish cohort of 103 FCCTX families failed to identify any rare candidate variants in this gene (Seguí et al., 2014) . Although only 45.6% of families in the Seguí et al. (2014) study met AC-1 and were truly FCCTX, the differences between this study and ours underscore the importance in recognizing the influence of population genetics as well as ascertainment criteria. A negative screening study in one population does not refute a role for GALNT12 in CRC.
Strong arguments exist for a role for GALNT12 in CRC pathogenesis. Genetic evidence demonstrates that GALNT12 resides within a CRC susceptibility locus, with both rare and functionally deleterious somatic and germline GALNT12 variants found in CRC patients (Clarke et al., 2012; Guda et al., 2009) . Moreover, GALNT12 is selectively expressed in intestinal epithelia and frequently downregulated in CRCs (Guo et al., 2002 , Guo et al., 2004 . Furthermore, GALNT12 has been identified as one of the key genes facilitating normal morphology and polarization in colon epithelial cells (Li et al., 2017) . GALNT12 is a key enzyme catalyzing the initiation of mucin-type O-glycosylation (Bennett et al., 2012) ; a pathway shown to play a critical role in CRC progression (Pinho & Reis, 2015; Stowell et al., 2015) . Mice deficient in intestinal mucin-type O-glycans spontaneously develop colitisassociated colon cancer due to inflammation resulting from impaired mucin barrier function (Bergstrom et al., 2016) . Moreover, mice lacking Muc2 spontaneously develop adenomas and CRC (Velcich et al., 2002) . Finally, recent studies of human glycosylation-associated genes from CRC-cell lines have identified candidates that are significantly mutated in CRC (Venkitachalam et al., 2016) .
Taken together, our findings suggest a thorough investigation for any putative link between GALNT12 and CRC progression is necessary. A broader approach for testing rare GALNT12 alleles in diverse populations, and characterizing their biological function in preclinical animal models may help decipher a role of GALNT12 in CRC pathogenesis. The discovery of moderate penetrance genes is an important avenue to explain the missing heritability in CRC. Although challenging, the characterization of these genes is poised to impart novel insights for interpreting cancer risk moving forward. Screening large and wellcharacterized cohorts, in unique populations, represents an important strategy moving forward.
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